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Stent Placement for Renal
Arterial Stenosis: Where Do
We Stand? A Meta-analysis1
PURPOSE: To perform a meta-analysis of renal arterial stent placement in compari-
son with renal percutaneous transluminal angioplasty (PTA) in patients with renal
arterial stenosis.
MATERIALS AND METHODS: Studies dealing with renal arterial stent placement
(14 articles; 678 patients) and renal PTA (10 articles; 644 patients) published up to
August 1998 were selected. A random-effects model was used to pool the data.
RESULTS: Renal arterial stent placement proved highly successful, with an initial
adequate performance in 98% and major complications in 11%. The overall cure
rate for hypertension was 20%, whereas hypertension was improved in 49%. Renal
function improved in 30% and stabilized in 38% of patients. The restenosis rate at
follow-up of 6–29 months was 17%. Stent placement had a higher technical success
rate and a lower restenosis rate than did renal PTA (98% vs 77% and 17% vs 26%,
respectively; P , .001). The complication rate was not different between the two
treatments. The cure rate for hypertension was higher and the improvement rate for
renal function was lower after stent placement than after renal PTA (20% vs 10% and
30% vs 38%, respectively; P , .001).
CONCLUSION: Renal arterial stent placement is technically superior and clinically
comparable to renal PTA alone.
In 1978, renal percutaneous transluminal angioplasty (PTA) was introduced by Gru¨ntzig et
al (1) as an alternative to surgical treatment for renal arterial stenosis. In subsequent years,
numerous studies (2) reported the beneficial effect of renal PTA on the management of
renovascular hypertension and renal function. Since then, renal PTA has become accepted
widely for treating renal arterial stenosis, although a restenosis rate of 27%–100% at
follow-up of 6–12 months has been acknowledged as a major limitation of the procedure
(3,4). In patients treated for atherosclerotic renal arterial stenosis, the effects on blood
pressure were disappointing, but in patients who had renal arterial stenosis owing to
fibromuscular dysplasia, renal PTA proved successful, with cure rates for hypertension of
22% versus 83% (5).
With the introduction of self-expanding and balloon-expandable metallic stents, a new
treatment that might overcome poor angioplasty results, immediate postangioplasty
complications, and restenosis became available for atherosclerotic renal arterial stenosis.
Since the early studies (6–8) of renal arterial stent placement in 1991, results of several case
series established the successful placement of stents for renal arterial stenosis. The purpose
of this study was to present an overview of studies about renal arterial stent placement and
to perform a meta-analysis of renal arterial stent placement in comparison with renal PTA
in patients with renal arterial stenosis.
MATERIALS AND METHODS
A literature review was performed of studies that deal with renal arterial stent placement
and that were identified by means of a MEDLINE search of the English-language medical
literature from January 1991 to August 1998. To avoid double counting, data from the most
recently published articles from a particular institution were included, thereby ignoring the
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possible additional information in previ-
ously published work. From the 14 ar-
ticles (678 patients [350 men, 328
women], 799 treated arteries) identified
(6–19), when available, the following data
were extracted: patient selection criteria,
lesion characteristics, procedure, anti-
thrombotic therapy, initial technical suc-
cess, complications, duration of follow-
up, clinical results, and restenosis rate.
Patients included in the survey had a
mean age of 66 years and an age range
from 55 (9) to 70 (12,17) years.
Data extraction was performed by the
first author (T.C.L.) and verified by a coau-
thor (E.J.G.). Discrepancies in the ex-
tracted data were resolved by these au-
thors examining the articles simultaneously.
The variables of initial technical suc-
cess rate, complication rate, clinical re-
sults, and restenosis rate across the stud-
ies were tested for homogeneity by using
the x2 test (two-sided, a 5 .05). As these
variables were not uniformly defined or
measured in identical conditions, a ran-
dom-effects model, as described by Laird
and Mosteller (20) in 1990, was used to
combine the data. The mean age of pa-
tients, mean number of stents per artery,
and mean period of clinical and angio-
graphic follow-up across studies were
combined by using weighted means.
The relationship between categoric vari-
ables was demonstrated in contingency
tables by using the x2 test; for continuous
variables, the Pearson product moment
correlation was calculated (SPSS for Win-
dows, version 7.0; SPSS, Chicago, Ill).
Correlation coefficients were determined
between patient age and the following
variables: lesion characteristics, stents per
artery, initial technical success, complica-
tion rate, percentage of patients in whom
hypertension or renal function was cured
or improved, and restenosis rates. Correla-
tion coefficients were considered worth
mentioning in the case of r values greater
than 0.50. Two-sided P values of .05 or
less were considered statistically signifi-
cant.
The results of stent placement in pa-
tients with renal arterial stenosis were
compared with the results of renal PTA in
a similar patient group (10 articles, 644
patients [261 men, 218 women, 165 sex
not mentioned], 778 arteries). Because
the majority of stent studies were pub-
lished from January 1995 to August 1998,
studies dealing with renal PTA for renal
arterial stenosis published in the same
period were included to obtain contempo-
rary controls (3,21–29). The following
parameters were compared between the
stent studies and the renal PTA studies:
indication for intervention, initial techni-
cal success, complication rate, percentage
of patients in whom hypertension or
renal function was cured or improved,
and restenosis rate. Comparison was per-
formed with the use of contingency tables
by using the x2 test (two-sided, a 5 .05) to
test for statistical significance. Patients
had a mean age of 64 years and an age
range from 59 (28) to 68 (23) years.
RESULTS
Pooled data for all patients who under-
went renal arterial stent placement (n 5
678) are listed in Tables 1 and 2.
Patient Selection Criteria
The criteria used for selecting patients
for stent placement varied widely. Clini-
cal indication for intervention was a com-
bination of hypertension and renal fail-
ure in all but four articles (10,15,17,18).
The number of patients treated for hyper-
tension (n 5 536) was higher than the
number of patients treated for renal func-
tion impairment (n 5 344). In 10 studies
(6–9,11,13–17), stent placement was per-
formed after initial or late renal PTA
failure. In two studies (12,19), stent place-
ment was the primary intervention, and
in the remaining two studies (10,18) stent
placement was used as a primary or sec-
TABLE 1
Patient Characteristics, Type of Stents Used, and Initial Angiographic Success Following Renal Arterial Stent Placement
Study
Patients
No. of
Arteries
Indication* Location†
Stent Initial Angiographic Success
No.
Age
(y) HT RF Ost Trunc
No. per
Artery Type
Criterion
for PDS‡ Success§ Complications\
Wilms et al (6) 11 60 12 10 1 6 6 1.25 Wallstent ,20 83 3 (25)
Kuhn et al (7) 10 56 10 9 10 0 10 1.40 Strecker ,20 80 4 (40)
Rees et al (8) 28 66 28 28 14 28 0 1.11 Palmaz ,30 96 5 (18)
Hennequin et al (9) 21 55 21 21 6 7 14 1.19 Wallstent ,30 100 4 (19)
van de Ven et al (10) 24 67 28 24 0 28 0 1.14 Palmaz ,10 100 3 (11)
Henry et al (11) 59 65 64 59 10 34 30 1.00 Palmaz ,20 100 2 (3)
Iannone et al (12) 63 70 83 63 29 51 32 1.00 Palmaz ,30 99 11 (13)
Blum et al (13) 68 60 74 68 20 74 0 1.03 Palmaz ,50 100 0 (0)
Boisclair et al (14) 33 63 35 33 17 19 16 1.00 Palmaz ,30 100 6 (17)
Harden et al (15) 32 67 32 0 32 NM NM 1.03 Palmaz ,10 100 1 (3)
White et al (16) 100 67 133 100 44 107 26 1.12 Palmaz ,30 99 2 (2)
Rundback et al (17) 45 70 54 0 45 NM NM NM Palmaz ,30 94 5 (9)
Shannon et al (18) 21 63 23 0 21 17 5 1.09 Palmaz NM 100 2 (9)
Dorros et al (19) 163 67 202 121 95 NM NM NM Palmaz ,50 100 23 (11)
Total or mean 678# 66** 799# 536# 344# 371# 139# 1.07** NA NA 98†† 11††
95% CI NA NA NA NA NA NA NA NA NA NA 95%, 100% 6%, 16%
Note.—NA 5 not applicable, NM 5 not mentioned.
* HT 5 hypertension, RF 5 renal failure.
† Ost 5 ostial, Trunc 5 truncal.
‡ PDS 5 percentage of diameter stenosis.
§ Data are the percentage of arteries.
\ Data are the number of arteries. Data in parentheses are percentages. Hematomas and puncture traumas are excluded.
# Total.
** Weighted mean.
†† Mean based on random-effects model.
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ondary intervention. The angiographic
definition of a hemodynamically signifi-
cant stenosis ranged from 40% to more
than 70% reduction in lumen diameter.
Lesion Characteristics
At angiography, a distinction was made
between ostial and truncal lesions and
between lesions due to atherosclerosis
and lesions due to fibromuscular dyspla-
sia. Ostial lesions were defined as stenoses
of the renal artery within 2 mm (18), 4
mm (17), or 5 mm (10,13) of the aortic
lumen. In one study (11), an ostial lesion
was defined as a stenosis without a non-
diseased renal arterial segment between
the lesion and the aorta. More ostial
lesions (n 5 371) than truncal lesions
(n 5 139) were treated. In seven articles
(6,9,11,12,14,16,18), either ostial or trun-
cal lesions were treated. In three studies
(8,10,13), only ostial lesions were treated,
and in one study (7), only truncal lesions
were involved. In the remaining three
studies (15,17,19), the location of the
lesion was not mentioned. Renal arterial
stenoses were atherosclerotic in origin in
the majority of cases. Patients also were
included with renal arterial stenosis due
to fibromuscular dysplasia (n 5 6), Takayasu
arteritis (n 5 2), and/or posttransplanta-
tion stenosis (n 5 4) (6,7,9,11,14).
Procedure
In 11 studies (6–14,17,18), the femoral
approach was used for access; the brachial
approach was used in the remainder
(15,16,19). Stent placement was preceded
by predilation or balloon angioplasty in
all but one study (19). The reason for
predilation was given in two studies: in
one study (8) to decrease the inflation
pressure required for stent expansion and
in the other study (16) to ensure that full
expansion of the lesion was possible. In
one study (7), the lesion was overdilated
up to 120% of the original vessel size
before stent placement. In the majority of
studies (n 5 11), the authors did not
describe the method used for vessel siz-
ing. In the remaining three studies (11,
12,16), digital angiographic analysis was
used. In 11 studies, the Palmaz stent was
used; in two studies (6,9), the Wallstent;
and in one study (7), the Strecker stent.
In four studies, overdilation of the stent
up to 110% (8,16) or 120% (13) of the
original vessel size or 0.5–1.0 mm larger
than the original vessel was performed
(7). The reason for this overdilation was
‘‘to compensate for neointimal growth and
to prevent the stent from migrating’’ (7).
For ostial lesions, a slight protrusion of
the stent into the aorta was recom-
mended in five studies (10,11,13,14,18).
In addition, in one study (11) the part of
the stent protruding into the aorta was
reshaped with the use of a larger balloon.
Antithrombotic Therapy
Prophylaxis against thrombosis during
the procedure was used in all studies, but
the regimens varied. These included a
2,000–10,000-IU bolus of heparin cal-
cium (6,7,9–11,13,16); a 1,000–5,000-IU
bolus of heparin calcium and 100–400 µg
of nitroglycerin (8,14,17,18); or a combi-
nation of 75 mg of dipyridamole, 325 mg
of acetylsalicylic acid, and mannitol hexa-
nitrate (10% solution injected intravenously
at a rate of 100 mL/h for 5 hours) (19).
In seven studies (6,7,9–11,13,14), hepa-
rin calcium was used intravenously for
anticoagulation the 1st days after renal
arterial stent placement and was titrated
to obtain a partial thromboplastin time
two to three times normal. The anticoagu-
TABLE 2
Clinical and Angiographic Follow-up in Patients Who Underwent Renal Arterial Stent Placement
Study
Clinical Follow-up
Angiographic Follow-up
Follow-up Hypertension* Renal Function*
Follow-up Restenosis
Patients* Time (mo) Cured Improved Improved Stabilized Arteries†
Time
(mo)
Criterion
for PDS‡ Rate†
Wilms et al (6) 100 7 30 40 0 0 58 7 NM 29
Kuhn et al (7) 80 11 29 43 50 NM 100 7 .50 25
Rees et al (8) 100 7 11 54 36 36 64 8 .50 39
Hennequin et al (9) 100 32 14 86 17 50 95 29 .70 20
van de Ven et al (10)§ 92 6 68 5 36 64 82 6 .50 13
Henry et al (11) 92 14 19 57 20 NM NM 6 .50 9
Iannone et al (12)\ 86 10 4 35 36 45 83 11 .60 14#
Blum et al (13) 100 27 16 62 NM NM 100 27 .50 11
Boisclair et al (14) 100 13 6 61 41 35 23 NP .50 NP
Harden et al (15) 100 6 NM NM 34 34 75 6 .50 13
White et al (16) 100 6 NM NM 20 NM 60 9 .50 19
Rundback et al (17) NM 17 NM NM NM NM 52 13 .50 25
Shannon et al (18)§ 100 9 NM NM 43 29 NM 9 .50 0
Dorros et al (19)\ 28 48 3 51 NM NM NP NM NM NP
Mean 91** 16†† 20‡‡ 49‡‡ 30‡‡ 38‡‡ 72** 17†† NA 17‡‡
95% CI NA NA 4%, 37% 16%, 83% 22%, 39% 25%, 51% NA NA NA 12%, 23%
Note.—NA 5 not applicable, NM 5 not mentioned, NP 5 not routinely performed.
* Data are percentages of patients.
† Data are percentages.
‡ PDS 5 percentage of diameter stenosis.
§ Primary and secondary stent placement.
\ Primary stent placement.
# Duplex restenosis.
** Mean.
†† Weighted mean. If the number of patients for follow-up was not reported, the mean was estimated from the number of arteries for follow-up and
vice versa. If angiographic follow-up was not reported, the mean was estimated from clinical follow-up data.
‡‡ Mean based on random-effects model.
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lation regimen at patient discharge was
changed to 100–300 mg of acetylsalicylic
acid per day (6,9–11), 660 mg of acetylsali-
cylic acid per day and 150 mg of dipyri-
damole per day (7), 100 mg of acetylsali-
cylic acid per day or 250 mg of ticlopidine
hydrochloride per day (13), or warfarin
potassium (14). In other studies, patients
used only 75–300 mg of acetylsalicylic
acid per day (18) or warfarin potassium
(international normalized ratio of 2.0–
2.5, 1–3 months) (16), or they used a
combination of acetylsalicylic acid, dipyri-
damole, and warfarin potassium (19). Pa-
tients in two studies (8,17) did not use
anticoagulation therapy routinely after
renal arterial stent placement, and the
authors of two other studies (12,15) did
not report the anticoagulation regimen.
Initial Technical Success
The initial technical success of the pro-
cedure reported was not significantly dif-
ferent among the studies. In two of the
earlier studies, successful stent placement
was achieved in 83% (6) and 80% (7) of
arteries, followed by success rates ranging
from 94% to 100% in subsequent studies
(Table 1). It should be noted, however,
that the definitions for technical success
ranged from less than 10% residual steno-
sis (10,15) to less than 50% residual steno-
sis (13,19).
Complications
Of the complications encountered, the
most frequently reported (n 5 40) were
hematoma formation and puncture
trauma. More severe complications in 71
(9%) of the 799 treated arteries included
renal failure (n 5 34; three fatal), segmen-
tal renal infarction (n 5 9), perinephric
hematoma (n 5 9; two fatal), renal arte-
rial thrombosis or occlusion (n 5 6), stent
misplacement (n 5 5), proteinuria (n 5
2), sepsis (n 5 1), brachial arterial occlu-
sion (n 5 1), mismatch of stent and vessel
(n 5 1), cholesterol embolism to the lower
extremities (n 5 1), dissection of the iliac
artery (n 5 1), and brachial arterial bleed-
ing (n 5 1; fatal). The mean mortality rate
related to the procedure was 1% (95% CI:
0%, 2%). The mortality rate usually in-
cluded deaths directly or indirectly re-
lated to the procedure within the 1st
month after stent placement (8,12,15,18).
In one study (18), the mortality rate
included a patient who died 6 months
after stent placement owing to rupture of
a pseudoaneurysm caused by the inter-
vention. In one study (19), the authors
did not mention the postprocedural pe-
riod in which the mortality rate was
calculated; therefore, data from this study
were not included in the mortality rate.
In addition, six other patients died of
causes described as not related to the
procedure. The complication rate varied
significantly across the studies (P , .001)
and was significantly lower in studies in
which Palmaz stents were used than those
in which other stent types were used (8%
vs 25%; P , .001); the mean complication
rate was 11% (95% CI: 6%, 16%) (Table 1).
Duration of Follow-up
The clinical follow-up period ranged
from 6 months (10,15,16) to 48 months
(19); for angiographic follow-up, 6 months
was the shortest interval (10,11,15), whereas
the longest follow-up was 29 months (9).
Clinical Results
The clinical effect of renal arterial stent
placement on blood pressure was ex-
pressed in terms of cure and improve-
ment, although neither classification was
defined uniformly. In most studies, ‘‘cure’’
was defined as a diastolic blood pressure
of 90 mm Hg or less without medication
(6,8,9,11–14). Other definitions of ‘‘cure’’
included blood pressure less than 160/95
mm Hg (10), blood pressure less than
160/95 mm Hg without medication (7),
and systolic blood pressure less than 160
mm Hg and/or diastolic blood pressure
less than 90 mm Hg without medication
(19). In addition, in one study (16) clini-
cal success was reported as systolic blood
pressure less than 150 mm Hg and dia-
stolic blood pressure less than 90 mm Hg
with the same or less medication than the
patient used before stent placement. Defi-
nitions used to describe improvement of
hypertension varied widely and are sum-
marized in Table 3.
More uniform criteria were used to
define the effect of renal arterial stent
placement on renal function in terms of
improvement, stabilization, and deterio-
ration. Renal function was considered
improved when the serum creatinine
values decreased more than 20%
(10,11,15,17,18), more than 15% (8,12,14),
or more than 18 µmol/L (19). Renal func-
tion was considered stabilized when the
change in serum creatinine values was
TABLE 3
Definitions Used to Describe Improvement of Blood Pressure Following
Renal Arterial Stent Placement
Study Definition
Wilms et al (6) Diastolic blood pressure decreased 15% or more and was greater than
90 mm Hg but less than 110 mm Hg
Kuhn et al (7) Decrease in systolic and diastolic blood pressure of 10 mm Hg or more,
the same or less medication
Rees et al (8) Diastolic blood pressure decreased 15 mm Hg or more with the same
or less medication, less medication, or diastolic blood pressure
decreased 15% or more and was greater than 90 mm Hg but less
than 110 mm Hg with the same or less medication
Hennequin et al (9) Diastolic blood pressure was less than 90 mm Hg with the same or less
medication, or diastolic blood pressure decreased 15% or more and
was greater than 90 mm Hg but less than 110 mm Hg with the same
or less medication
van de Ven et al (10) Decrease in mean arterial pressure of 20% or more
Henry et al (11) Diastolic blood pressure decreased 15% or more with the same or less
medication
Iannone et al (12) Diastolic blood pressure was less than 90 mm Hg and less medication,
or diastolic blood pressure was greater than 90 mm Hg and
decreased 10 mm Hg more with less medication
Blum et al (13) Diastolic blood pressure of 91–110 mm Hg and a decrease of 15% or
more; or diastolic blood pressure of 91–110 mm Hg, a decrease of
10% or more, and one or more fewer medications
Boisclair et al (14) Diastolic blood pressure was less than 90 mm Hg or 90–110 mm Hg, a
decrease of 15% or more with the same or less medication
Harden et al (15) Not mentioned
White et al (16) Systolic blood pressure was less than 150 mm Hg and diastolic blood
pressure was less than 90 mm Hg with the same or less medication
Rundback et al (17) Not mentioned
Shannon et al (18) Not mentioned
Dorros et al (19) Systolic or diastolic blood pressure decreased 10% or more or 15% or
more with the same medication, or systolic or diastolic blood pres-
sure remained the same or decreased less than 10% or less than 15%
with less medication
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less than these values and deteriorated
when serum creatinine values increased
according to these values. In five studies
(6,7,9,13,16), no criteria for change in
renal function were provided.
The percentage of patients in whom
hypertension was cured (20%; 95% CI:
4%, 37%) was not uniform among the
studies (P , .001) (Table 2). The percent-
age of patients in whom hypertension
improved as a result of renal arterial stent
placement was higher (49%; 95% CI:
16%, 83%) and differed significantly
among the studies (P , .001). No study
results showed a significant decrease in
overall serum creatinine values after stent
placement. Renal function in patients
with renal failure was improved in 30%
(95% CI: 22%, 39%) and stabilized in
38% (95% CI: 25%, 51%) of patients.
These results did not vary significantly
across the studies (improvement, P 5 .13;
stabilization, P 5 .11) (Table 2).
Restenosis Rate
Angiographic follow-up was performed
in all but three studies: In two studies
(14,19), follow-up angiography was not
performed routinely, and in one study
(12), duplex ultrasonography (US) was
used for detection of restenosis. The defi-
nitions used for restenosis were not uni-
form among the studies. The criterion of
stenosis of more than 50% of the diam-
eter was used for restenosis in most stud-
ies. Stenosis of more than 60% (12) and
stenosis of more than 70% (9) were also
criteria for restenosis. Unclear, however,
was whether the percentages were calcu-
lated at the stent site (local stenosis) or
were calculated in comparison with the
reference site (relative stenosis). This may
have caused considerable variation among
the reviewed studies. The overall resteno-
sis rate after renal arterial stent placement,
depending on the angiographic defini-
tion, was 17% (95% CI: 12%, 23%) and
ranged from 0% (18) to 39% (8) (P 5 .04).
Relationship between Variables
Calculation of correlation between vari-
ables showed that older patients had more
ostial lesions (r 5 0.61; P 5 .05), signifi-
cantly fewer stents per artery (r 5 20.65;
P 5 .02), and a significantly lower compli-
cation rate (r 5 20.56; P 5 .04) than did
younger patients. Patient age was signifi-
cantly related with success rate for hyper-
tension: the older the patient, the smaller
the effect on blood pressure (r 5 20.77;
P 5 .009).
Comparison with Renal PTA
Renal PTA data are given in Tables 4
and 5. The patient groups for stent place-
ment and renal PTA showed significant
differences in indication for intervention
and the location of the lesion involved.
In the stent studies, more patients with
renal failure and more ostial lesions were
included than in the renal PTA studies
(P , .02 and P , .001, respectively). The
technical success rate was significantly
higher after stent placement compared with
that after renal PTA alone (98% and 77%,
respectively; P , .001). The complication
rate was not significantly different between
stent placement and renal PTA alone (11%
and 13%, respectively; .2 , P , .3).
The proportion of patients in whom
hypertension was cured was significantly
different: 20% after stent placement and
10% after renal PTA (P , .001). The
proportion of patients with improvement
of hypertension was similar for both treat-
ment strategies (49% and 53%, respec-
tively; .1 , P , .2). The percentage of
patients with improved renal function
was significantly lower for stent place-
ment than for renal PTA (30% vs 38%,
respectively; P , .001). Restenosis rates,
however, were significantly lower after
stent placement than after renal PTA alone
(17% and 26%, respectively; P , .001).
DISCUSSION
Review of 14 articles concerning patients
with hypertension, renal failure, or both
indicated that renal arterial stent place-
TABLE 4
Patient Characteristics and Initial Angiographic Success Following Renal PTA
Study
Patients
No. of
Arteries
Indication* Location†
Initial Angiographic Success
No.
Age
(y) HT RF Ost Trunc
Criterion
for PDS‡ Success§ Complications\
Karagiannis et al (21) 62 65 76 62 27 NM NM ,50 72 3 (4)
Jensen et al (22) 107 63 147 NM NM NM NM NM 82 8 (5)
Eldrup-Jorgensen et al (23) 52 68 60 10 42 NM NM NM 92 3 (5)
Bonelli et al (24) 190 64 242 NM NM 53 189 ,30 82 56 (23)
von Knorring et al (25) 38# 60 38 38 0 9 29 NM NM NM
Tullis et al (26) 41 65 52 41 0 29 23 ,60** 75 NM
Baumgartner et al (27) 56 60 63 25 25 NM NM ,60** NA NM
Hoffman et al (3) 50 66 52 46 36 52 0 ,30 58 9 (17)
Plouin et al (28) 23 59 23 23 0 7 16 NM NM 6 (26)
Webster et al (29) 25 60 25 25 0 13 12 NM NM 3 (12)
Total or mean 644†† 64‡‡ 778†† 270†† 130†† 163†† 269†† NA 77§§ 13§§
95% CI NA NA NA NA NA NA NA NA 68%, 86% 6%, 19%
Note.—NA 5 not applicable, NM 5 not mentioned.
* HT 5 hypertension, RF 5 renal failure.
† Ost 5 ostial, Trunc 5 truncal.
‡ PDS 5 percentage of diameter stenosis.
§ Data are the percentage of arteries.
\ Data are the number of arteries. Data in parentheses are percentages. Hematomas and puncture traumas are excluded.
# Only patients with atherosclerotic renal arterial stenosis are included.
** Based on duplex US.
†† Total.
‡‡ Weighted mean.
§§ Mean based on random-effects model.
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ment is an attractive treatment with a
high initial success rate (98%) and a mean
restenosis rate of 17% at a mean fol-
low-up of 17 months. At clinical fol-
low-up of 6–48 months, hypertension
was cured in 20% of the patients and
improved in 49%. Renal function in the
patients with impaired renal function
was improved in 30% and stabilized in
38%.
In the early studies, most of the pa-
tients were included in order to assess the
effects on blood pressure. In later studies
(15,17,18), the authors assessed the effect
on renal function in patients with renal
failure, regardless of the presence of hyper-
tension. Although the minority of pa-
tients with chronic renal failure have
renovascular disease, intervention by
means of renal PTA or stent placement in
renal failure associated with renovascular
disease seems worthwhile, since stenosis
of the renal artery is one of the few
correctable causes of renal failure.
In most of the reviewed studies, second-
ary renal arterial stent placement was
performed (ie, after initial or late failure
of renal PTA). In some studies, however,
primary stent placement or combined
primary or secondary stent placement
was performed. Patients undergoing sec-
ondary stent placement after unsuccess-
ful renal PTA may have more severe renal
arterial disease and are therefore perhaps
more difficult to treat with stent place-
ment than patients undergoing primary
stent placement. This phenomenon could
have caused a selection bias and makes
comparison between studies of technical
and clinical results difficult.
The majority of patients selected had
atherosclerotic renal arterial stenosis. Ac-
cording to the literature, the outcome of
renal PTA for renal arterial stenoses due to
fibromuscular dysplasia appears to be
much better than that for atherosclerotic
stenoses (2). No conclusions could be
drawn about the value of stent placement
for fibromuscular dysplasia because these
patients were underrepresented in this
review.
Most investigators used the Palmaz
stent; the authors of only three studies
(6,7,9) used other stent types. Clinical
success and restenosis rates in these series
did not differ substantially from those
reported with Palmaz stents. Complica-
tion rates, however, were higher in the
studies in which Palmaz stents were not
used, but these results have to be inter-
preted with caution because other stent
types were used in only three studies. In
the studies (6,9) in which Wallstents were
used, problems were encountered with
stent visibility at fluoroscopy. This is of
utmost importance for correct stent place-
ment, especially when the selected
stent is short. The femoral approach for
access into the renal artery was used
commonly in the reviewed studies and
seemed to be safer than the brachial
approach, which is illustrated by the case
of the patient who died owing to uncon-
trolled bleeding from a brachial puncture
site (15).
In the reviewed studies, no specific
relation was found between the anti-
thrombotic therapy used and the out-
come and complications of the interven-
tion. Antithrombotic therapy is warranted
to prevent thrombosis, but at the same
time substantial bleeding complications
should be avoided.
The initial technical success of renal
arterial stent placement was high and
agreed with success rates of stent place-
ment in coronary arteries (30,31). How-
ever, the difference in angiographic defi-
nitions used for technical success made
adequate comparison difficult. We used
intravascular US following angiographi-
cally successful renal arterial stent place-
ment and found that intravascular US
data warranted further increase of vessel
dimensions in 33% (six of 18) of patients
(32). Results of future studies will show
whether renal arterial stent placement
guided by intravascular US is beneficial
for the long-term outcome.
TABLE 5
Clinical and Angiographic Follow-up in Patients Who Underwent Renal PTA
Study
Clinical Follow-up Angiographic Follow-up
Follow-up
Hypertension* Renal Function*
Follow-up Restenosis
Patients*
Time
(mo) Cured Improved Improved Stabilized Arteries†
Time
(mo)
Criterion
for PDS‡ Rate†§
Karagiannis et al (21) 48 40 19 52 22 50 NM NM NM NP
Jensen et al (22) 78 12 12 40 NM NM 77 12 .75 9
Eldrup-Jorgensen et al (23) NM 28 NM NM NM NM NM NM NM NP
Bonelli et al (24) NM 33 8 62 NM NM NM 22 .70 NP
von Knorring et al (25) 71 48 11 74 NM NM NM 48 NM NM
Tullis et al (26) 35 28 11 33 50 40 35 24 .60 55
Baumgartner et al (27) 70 13 9 46 48 36 NM 13 .60\ 28
Hoffman et al (3) 49 21 2 64 32 36 50 11 .50 27
Plouin et al (28) 23 6 NM NM NM NM 100 6 .50 13
Webster et al (29) 25 NM NM NM NM NM 35 12 NM NM
Mean 50# 22** 10†† 53†† 38†† 41†† 59# 19**‡‡ NA 26††
95% CI NA NA 7%, 14% 42%, 63% 25%, 51% 35%, 48% NA NA NA 11%, 42%
Note.—NA 5 not applicable, NM 5 not mentioned.
* Data are percentages of patients.
† Data are percentages.
‡ PDS 5 percentage of diameter stenosis.
§ NP 5 not standardly performed.
\ Based on duplex US.
# Mean.
** Weighted mean.
†† Mean based on random-effects model.
‡‡ If the number of patients for follow-up was not reported, the mean was estimated from the number of arteries for follow-up and vice versa. If clinical
follow-up was not reported, the mean was estimated from angiographic follow-up data.
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The initial technical success rate of
stent placement was consistently high
(.80%). The complication rate encoun-
tered (11%) varied among the studies
reviewed. The cause of the difference in
complication rates between the studies
(0%–40%) remains speculative. The mor-
tality rate due to renal arterial stent place-
ment was the same as that previously
reported after coronary arterial stent
placement (1% [three of 259]) (33).
After review of the results of renal
arterial stent placement for renovascular
disease, it appears that there is no univer-
sally accepted reporting standard. Al-
though all articles describe a decrease in
systolic and diastolic blood pressure after
stent placement, there is much variation
in definitions for ‘‘cure’’ and ‘‘improve-
ment’’ of hypertension. This aspect ham-
pered adequate comparison between the
studies and may explain the difference in
clinical results achieved.
In addition, the adjustment of antihy-
pertensive drugs after stent placement
was not sufficiently described and quanti-
fied. The actual effect of stent placement
on blood pressure in these uncontrolled
studies, therefore, remains elusive, espe-
cially when one bears in mind that blood
pressure also can be lowered by means of
medication alone (28). Reporting all ac-
tual blood pressure data, as well as the
amount and type of antihypertensive
drugs used, may allow a more accurate
comparison of the results of various stud-
ies. The best way to express the amount of
antihypertensive drugs is, to our knowl-
edge, the calculation of defined daily
doses, or DDDs, according to the World
Health Organization, to reflect both the
number and doses of the prescribed drugs
(34).
In agreement with results obtained af-
ter renal PTA, a beneficial effect of renal
arterial stent placement on renal func-
tion has not been established convinc-
ingly. Nevertheless, renal function in 30%
of the patients with renal failure was
regarded as improved and in 38%, as
stabilized, which may indicate that the
effect of stent placement on renal func-
tion may be stabilization rather than sta-
tistically significant improvement.
It is noteworthy that the most recent
studies (15,17,18) focused on the effect of
renal arterial stent placement on the man-
agement of renal function, whereas the
effects on hypertension seemed to be of
less importance. This shift of focus from
hypertension to renal function seems un-
justified in regard to the blood pressure
and renal function data among the stud-
ies reviewed. It should be noted, however,
that hypertension was the subject of nu-
merous previous studies, and renal func-
tion has been ignored somewhat, which
may have been corrected in the later
studies.
The mean restenosis rate of 17% (range,
0%–39%) after follow-up of 6–29 months
after renal arterial stent placement agreed
with restenosis rates in coronary arteries
(35). Restenosis rates after stent place-
ment were significantly lower than those
after renal PTA alone, although a random-
ized trial is warranted to investigate this
topic in more detail. The cause of the
different restenosis rates among the stud-
ies was not established clearly, nor were
the mechanisms related to restenosis.
Calculation of correlations between the
different variables revealed that older pa-
tients had less benefit from stent place-
ment with regard to hypertension than
did younger patients. This may reflect the
coexistence of essential hypertension and
irreversible arteriolosclerosis in older pa-
tients. A serious limitation associated with
the calculation of correlations between
the different variables across the studies is
the absence of raw data. The fact that, for
example, one patient may have under-
gone two stent placement procedures
could not be taken into account in an
analysis as presented in this study. There-
fore, conclusions must be interpreted care-
fully. For the same reason, we were un-
able to perform a multivariate regression
analysis, which might have established
the prediction of intervention outcome
on the basis of patient or lesion character-
istics. The results of our study, however,
demonstrate that such an analysis would
be interesting to perform.
Comparison between stent placement
and renal PTA showed higher initial suc-
cess rates and lower restenosis rates after
stent placement. The percentage of pa-
tients in whom hypertension was cured
tended to be higher after stent placement
than after renal PTA. The results as pre-
sented here were in accordance with the
results of the randomized trial in which
renal arterial stent placement was com-
pared with renal PTA (36). In that study
(36), renal arterial stent placement was a
better technique than renal PTA to achieve
vessel patency with higher technical suc-
cess and lower restenosis rates (88% vs
57% and 14% vs 48%, respectively). The
clinical outcome, however, was not sig-
nificantly different between stent place-
ment and renal PTA. In the meta-analysis
presented here, stent placement was asso-
ciated with a lower percentage of patients
with improved renal function. This may
be because the stent studies included
more patients with impaired renal func-
tion instead of hypertension, which may
affect the clinical outcome in terms of
renal function.
The major limitation of the present
study is that it is not a randomized con-
trolled clinical trial. Although random-
ized controlled clinical trials are the supe-
rior mode for evaluating and comparing
therapeutic interventions, they also have
limitations (37). First, a randomized trial,
performed in an ideal setting with a se-
lected, usually small, patient population,
may hamper generalization of the results.
Second, these trials are costly and often
have a short follow-up period for both
practical and ethical reasons. Meta-analy-
sis of cohort studies, on the other hand,
may reflect the general clinical practice, is
cheaper, supplies additional data about a
larger number of patients, and may be a
reasonable alternative to a randomized
controlled clinical trial. However, a meta-
analysis as presented here has well-known
deficits, including unequal numbers of
patients and different end points in
the studies. A multicenter trial with uni-
form patient entry criteria and outcome
measurements would provide valuable
results.
The following issues need to be ad-
dressed in future studies: (a) The assess-
ment of the outcome of renal PTA, stent
placement, and optimal medical therapy
in a randomized controlled setting. (b) The
long-term effects of treatments on blood
pressure, renal function, and restenosis
rates. Accurate monitoring of the amount
of antihypertensive medication in de-
fined daily doses is of critical importance,
since inaccuracies blur the outcome of
the intervention. (c) Optimal depiction of
the effect of endovascular renovascular
intervention. Possible modalities are intra-
vascular US (32) and magnetic resonance
angiography (38).
Renal arterial stent placement appears
to be superior, regarding initial success
and restenosis rates, and clinically compa-
rable to renal PTA alone. Future studies
are needed to focus on the prevention of
complications and on the assessment of
long-term benefit, as well as on the fac-
tors determining success or clinical fail-
ure of the intervention.
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